Insider · CIK 0001611157
Jack Y. Zhang
ceoofficerdirectorowner
Files at AMPH (Amphastar Pharmaceuticals, Inc.). First filing Jan 10, 2024, latest Jan 11, 2024.
In brief
Jack Y. Zhang files SEC Form 4 as CEO, director and 10% owner at AMPH (Amphastar Pharmaceuticals, Inc.). Since Jan 10, 2024, Jack Y. Zhang has reported 0 open-market buys worth $0 and 2 open-market sells worth $20M, the latest filed on Jan 11, 2024.
A track record needs three past buys with six months of prices behind them; Jack Y. Zhang has 0, so none is measured yet.
The newest scored trade: sold $7.2M of AMPH on Jan 10, 2024, filed Jan 11, 2024, scored 43 (moderate), under a 10b5-1 plan.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $20M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AMPH: Amphastar Pharmaceuticals, Inc.
AMPHOct 9, 2026 · close 26.62
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Amphastar Pharmaceuticals, Inc. | $7.2M 131,386 shares | -11% | +95% from low-16% from high | |
| 43Moderate | Amphastar Pharmaceuticals, Inc. | $13M 219,800 shares | -15% | +112% from low-9% from high |
Transactions
The newest 50 of 62 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 15, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -9,784 | $18.18 | $178k | 2,990,052 | Mar 17, 2026 |
| Mar 15, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -2,908 | $18.18 | $53k | 1,245,125 | Mar 17, 2026 |
| Mar 9, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stock | +180,504 | $0.00 | $0 | 3,014,621 | Mar 11, 2026 |
| Mar 10, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -14,785 | $18.91 | $280k | 2,999,836 | Mar 11, 2026 |
| Mar 9, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stockindirect: See footnote | +72,462 | $0.00 | $0 | 1,252,428 | Mar 11, 2026 |
| Mar 10, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -4,395 | $18.91 | $83k | 1,248,033 | Mar 11, 2026 |
| Mar 9, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +372,338 | $0.00 | $0 | 372,338 | Mar 11, 2026 |
| Mar 9, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivativeindirect: See footnote | +149,472 | $0.00 | $0 | 149,472 | Mar 11, 2026 |
| Mar 6, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -7,773 | $19.34 | $150k | 2,834,117 | Mar 10, 2026 |
| Mar 6, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -3,077 | $19.34 | $60k | 1,179,966 | Mar 10, 2026 |
| Mar 4, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -5,769 | $19.96 | $115k | 2,841,890 | Mar 6, 2026 |
| Mar 4, 2026 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -2,432 | $19.96 | $49k | 1,183,043 | Mar 6, 2026 |
| Jun 13, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Common Stock | +200,000 | $13.03 | $2.6M | 2,847,659 | Jun 16, 2025 |
| Jun 13, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -200,000 | $0.00 | $0 | 205,003 | Jun 16, 2025 |
| Mar 14, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Common Stock | +290,477 | $14.69 | $4.3M | 2,899,859 | Mar 18, 2025 |
| Mar 14, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -226,285 | $26.66 | $6.0M | 2,673,574 | Mar 18, 2025 |
| Mar 15, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -9,765 | $26.66 | $260k | 2,663,809 | Mar 18, 2025 |
| Mar 17, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -16,150 | $27.69 | $447k | 2,647,659 | Mar 18, 2025 |
| Mar 14, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Common Stockindirect: See footnote | +211,213 | $14.69 | $3.1M | 1,359,470 | Mar 18, 2025 |
| Mar 14, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -162,657 | $26.66 | $4.3M | 1,196,813 | Mar 18, 2025 |
| Mar 15, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -4,115 | $26.66 | $110k | 1,192,698 | Mar 18, 2025 |
| Mar 17, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -7,223 | $27.69 | $200k | 1,185,475 | Mar 18, 2025 |
| Mar 14, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -290,477 | $0.00 | $0 | 0 | Mar 18, 2025 |
| Mar 14, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Employee Stock Option (right to buy)derivativeindirect: See footnote | -211,213 | $0.00 | $0 | 0 | Mar 18, 2025 |
| Mar 10, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stock | +116,226 | $0.00 | $0 | 2,609,382 | Mar 12, 2025 |
| Mar 10, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stockindirect: See footnote | +48,996 | $0.00 | $0 | 1,148,257 | Mar 12, 2025 |
| Mar 10, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +246,821 | $0.00 | $0 | 246,821 | Mar 12, 2025 |
| Mar 10, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivativeindirect: See footnote | +104,052 | $0.00 | $0 | 104,052 | Mar 12, 2025 |
| Mar 6, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -9,645 | $28.32 | $273k | 2,493,156 | Mar 10, 2025 |
| Mar 6, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -3,069 | $28.32 | $87k | 1,099,261 | Mar 10, 2025 |
| Mar 4, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -5,753 | $27.62 | $159k | 2,502,801 | Mar 6, 2025 |
| Mar 4, 2025 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -2,426 | $27.62 | $67k | 1,102,330 | Mar 6, 2025 |
| Nov 11, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | GGift Common Stock | -125,000 | $0.00 | $0 | 2,508,554 | Nov 12, 2024 |
| Nov 11, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | GGift Common Stockindirect: See footnote | -125,000 | $0.00 | $0 | 1,104,756 | Nov 12, 2024 |
| Mar 15, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Common Stock | +722,046 | $12.46 | $9.0M | 2,858,043 | Mar 19, 2024 |
| Mar 15, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -408,721 | $43.05 | $18M | 2,449,322 | Mar 19, 2024 |
| Mar 17, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -15,768 | $43.05 | $679k | 2,433,554 | Mar 19, 2024 |
| Mar 15, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Common Stockindirect: See footnote | +310,930 | $12.46 | $3.9M | 1,439,466 | Mar 19, 2024 |
| Mar 15, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -202,658 | $43.05 | $8.7M | 1,236,808 | Mar 19, 2024 |
| Mar 17, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -7,052 | $43.05 | $304k | 1,229,756 | Mar 19, 2024 |
| Mar 15, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Employee Stock Option (right to buy)derivative | -722,046 | $0.00 | $0 | 0 | Mar 19, 2024 |
| Mar 15, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | MOption exercise Employee Stock Option (right to buy)derivativeindirect: See footnote | -310,930 | $0.00 | $0 | 0 | Mar 19, 2024 |
| Mar 6, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stock | -7,031 | $46.31 | $326k | 2,135,997 | Mar 8, 2024 |
| Mar 6, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | FTax withholding Common Stockindirect: See footnote | -2,990 | $46.31 | $138k | 1,128,536 | Mar 8, 2024 |
| Mar 4, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stock | +64,310 | $0.00 | $0 | 2,143,028 | Mar 6, 2024 |
| Mar 4, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Common Stockindirect: See footnote | +27,110 | $0.00 | $0 | 1,131,526 | Mar 6, 2024 |
| Mar 4, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +135,473 | $0.00 | $0 | 135,473 | Mar 6, 2024 |
| Mar 4, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivativeindirect: See footnote | +57,109 | $0.00 | $0 | 57,109 | Mar 6, 2024 |
| Jan 10, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -78,236 | $54.32 | $4.2M | 1,157,566 | Jan 11, 2024 |
| Jan 10, 2024 | AMPH Amphastar Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -50,514 | $54.89 | $2.8M | 1,107,052 | Jan 11, 2024 |
50 of 62 rows shown.
Questions about Jack Y. Zhang
Answered from the filings on this page, as of the latest one.
Is Jack Y. Zhang buying or selling?
Not in the last 12 months. Jack Y. Zhang's latest open-market trade on SEC Form 4 was sold $7.2M of AMPH on Jan 10, 2024.
How did Jack Y. Zhang's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jack Y. Zhang has 0.
Where does Jack Y. Zhang file Form 4?
Jack Y. Zhang has filed Form 4 at AMPH (Amphastar Pharmaceuticals, Inc.) as CEO & Chief Scientific Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.